skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Conceptualization of depression in Parkinson’s disease

(1878) Views  (444) Full article downloads

Authors: Jeffrey CL Looi, May Matias, Michelle J Ruzich

Published Date February 2005 Volume 2005:1(2) Pages 135 - 143
DOI: http://dx.doi.org/10.2147/NDT.S

Jeffrey CL Looi1,2,3, May Matias1,2, Michelle J Ruzich1,2,4

1Faculty of Medicine and Centre for Mental Health Research, Australian National University (ANU), Canberra, ACT, Australia; 2Research Centre for the Neurosciences of Ageing (RESCENA), ACT Health, Canberra, ACT, Australia; 3Laboratory of Neuroimaging, UCLA School of Medicine, Los Angeles, CA, USA; 4NSW Institute of Psychiatry, Parramatta, NSW, Australia

Aims: To discuss the current methodological and conceptual difficulties inherent in characterizing the emotional manifestations of neurodegenerative disease through critically reviewing depression as a manifestation of idiopathic Parkinson’s disease (PD).

Methods: Selective literature review of the neurobiological, psychological, and physical basis of depressive symptoms in PD from 1993–2003, with reference to key earlier articles.

Conclusions: There are difficulties in defining the syndromes of PD itself as well as depression in PD. The use of more conceptually reductionistic definitions of emotion and behavior in comprehensive longitudinal studies of the natural history of PD is recommended.

Keywords: Parkinson’s disease, depression, nosology








Readers of this article also read:

Frontotemporal dementia: remembering images from the past
Cognitive decline tracks motor progression and not disease duration in Parkinson patients
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
Antimicrobial prophylaxis in open lower extremity fractures
Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids
A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose
Update on pediatric dystonias: etiology, epidemiology, and management